Dual renin-angiotensin system blockade at optimal doses for proteinuria
- 1 September 2002
- journal article
- clinical trial
- Published by Elsevier BV in Kidney International
- Vol. 62 (3), 1020-1025
- https://doi.org/10.1046/j.1523-1755.2002.00536.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuriaAmerican Journal of Kidney Diseases, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Proteinuria as a modifiable risk factor for the progression of non-diabetic renal diseaseKidney International, 2001
- Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal DiseaseAnnals of Internal Medicine, 2001
- Dosing angiotensin II blockers—beyond blood pressureNephrology Dialysis Transplantation, 1999
- Renoprotective therapy: titration against urinary protein excretionThe Lancet, 1999
- Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockadeKidney International, 1998
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993
- Long-Term Benefits of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition in Nondiabetic Renal DiseaseAmerican Journal of Kidney Diseases, 1993